Peptides are not just for anti aging and research purposes, as many people have come to understand. They do have a whole range of applications, especially in medicine, where they are currently used in the development of new anti-angiogenic properties, which have been found to be effective in deterring various simulations of angiogenesis.
Angiogenesis is an important process in the growth and progression of malignant tumors and tissues. It is what normally is used by doctors to determine the extent to which cancer has spread in the body.
Through research, it has been determined that when the flow of blood to the tumours is restricted by interfering with angiogenesis and metastasis as well, the growth of tumors can be put in check. The current drugs being used as anti-angiogenesis work by targeting specific stimulators, though they are limited in their ability to reduce the tumor burden and prolong life.
Some of the peptides developed, as well as some still under development by the National Research Council Canada has exhibited direct anti-tumoregenic properties for various kinds of tumors and such findings have now been validated in living organisms. The action of the anti-angiogenic agents against multiple stimulators as well as their ability to inhibit the growth of tumors is a promising development in the fight against cancer and other malignant tumors.
How the anti-angiogenic agents work
Anti-angiogenics essentially work by inhibiting the angiogenic responses occasioned by different kinds of growth hormones. They stop the direct anti-tumoregenic properties against various kinds of cancerous cells and tumors. The National Research Council Canada has established and has also demonstrated that the anti-angiogenic and anti-tumoregenic actions of peptides are present at the C-terminal sequence of the proteins and they are partly assisted by the activities of intracellular cathespin B and L in the tumor cells.